TGF-β controls Akt activity and Foxo3a localization in CML LSCs, and Akt activity is suppressed despite BCR-ABL expression in vivo, leading to increased nuclear localization of Foxo3a [82]. This evidence concerns the gene AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive.